Maia Biotechnology, INC Form 4 insider transactions

Director Stan Smith of MAIA Biotechnology, Inc. purchased 25,000 shares of common stock and 25,000 warrants on December 13, 2024.

Ramiro Guerrero, a director at MAIA Biotechnology, purchased 53,418 shares of common stock and warrants on December 13, 2024.

Vlad Vitoc, CEO of MAIA Biotechnology, gifted stock options to irrevocable trusts for the benefit of his children, disclaiming beneficial ownership except for his pecuniary interest.

Director Cristian Luput purchased shares and warrants of MAIA Biotechnology, Inc. on November 1, 2024, according to a Form 4 filing.

Director Steven M. Chaouki purchased 22,133 shares of common stock and warrants of MAIA Biotechnology, Inc. on November 1, 2024.

Director Ramiro Guerrero purchased MAIA Biotechnology common stock and warrants on November 1, 2024.

Director Stan Smith purchased 100,000 shares of MAIA Biotechnology and related warrants on November 1, 2024, increasing his indirect holdings.

Director Steven M. Chaouki reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology through a Form 4 filing with the SEC.

Director Ramiro Guerrero reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Cristian Luput reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Louie Ngar Yee reports acquisition of stock options in MAIA Biotechnology, Inc.

Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., reported the acquisition of stock options on October 1, 2024.

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Ramiro Guerrero reports acquisition of 5,728 stock options in MAIA Biotechnology, Inc.

Director Steven M. Chaouki acquired 5,728 stock options in MAIA Biotechnology, Inc. on June 30, 2024.

Director Cristian Luput reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Louie Ngar Yee reports the acquisition of stock options in MAIA Biotechnology, Inc.

Director Jean-Manasse Theagene acquired 5,728 stock options in MAIA Biotechnology, Inc. on June 30, 2024.

Chief Scientific Officer Sergei Gryaznov reports the acquisition of stock options in MAIA Biotechnology, Inc.

Jeffrey Himmelreich, Head of Finance at MAIA Biotechnology, Inc., reports the acquisition of stock options.

Vlad Vitoc, CEO of MAIA Biotechnology, reports the acquisition of 200,000 stock options.

Director Louie Ngar Yee purchased 19,665 shares of common stock and warrants of MAIA Biotechnology, Inc. on April 25, 2024.

Director Stan Smith reports the acquisition of MAIA Biotechnology shares and warrants through a recent transaction.

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology through a grant under the company's 2021 Equity Incentive Plan.

Director Louie Ngar Yee reports the acquisition of 13,790 stock options in MAIA Biotechnology, Inc. on March 31, 2024.

Director Steven M. Chaouki acquired 9,193 stock options in MAIA Biotechnology, Inc. on March 31, 2024.

Director Ramiro Guerrero acquired 9,193 stock options in MAIA Biotechnology, Inc. on March 31, 2024.

Director Cristian Luput reports acquisition of stock options in MAIA Biotechnology, Inc.

Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., acquired 9,193 stock options on March 31, 2024.